St. Jude Children's Research Hospital structural biologists have deciphered how the structure of the enzyme called Abl regulates its activity, enabling the enzyme to switch itself on and off. Understanding Abl's regulation ...
Sep 26, 2017
0
26
Imagine you had a life-threatening cancer that a wonder drug had kept in remission for years. Would you risk quitting?
Mar 2, 2017
0
3
Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time. In ...
Sep 15, 2016
0
56
(HealthDay)—Nilotinib is associated with scurvy, possibly because of its effects on cutaneous metabolism, according to a letter to the editor published online April 28 in the Journal of Cutaneous Pathology.
May 11, 2016
0
1
Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have discovered that a protein produced by a cancer gene leads to the development of a deadly, late-stage form of prostate ...
Apr 1, 2016
0
6
University of Alabama at Birmingham researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia, or CML, today—an inability to get patients off treatment.
Feb 16, 2016
1
58
Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have pinpointed five specific enzymes called protein kinases that play a role when prostate cancer spreads to bone. The discovery ...
Dec 2, 2015
0
60
A new study by researchers at University of California, San Diego School of Medicine reveals a protein's critical - and previously unknown—role in the development and progression of acute myeloid leukemia (AML), a fast-growing ...
Jul 23, 2015
0
21
The Hong Kong Polytechnic University (PolyU) has achieved a breakthrough in the cancer genomics by developing a novel big data analysis platform for analyzing the interactions among genes. The analysis platform unveils the ...
Jun 23, 2015
0
22
Treating hematologic malignancies upfront with a combination of drugs based on the vulnerabilities of tumors as they evolve may be a viable strategy to avoid drug resistance, according to data presented at the American Association ...
Sep 23, 2014
0
0
